近日，据福布斯发布数据显示，全球仅13位女性凭借创建医疗健康企业跻身亿万富豪之列。值得关注的是，其中7位女性来自中国。在医疗健康行业，中 国女富豪们可谓「顶起了半边天」。 「DeepSeek时刻」 继AI产业之后，中国生物医药行业迎来「DeepSeek时刻」。 目前，全球生物制药行业正在经历"翻天覆地的变化"，中国正从曾经的"仿制药大国"崛起为挑战西方创新制药主导地位的新力量。中国生物技术的进步与 中国在人工智能（AI）和电动汽车领域的突破一样迅猛，超越了欧盟，赶上了美国。 数据分析显示，中国2024年进入研发阶段的新型药物（涵盖癌症、减重等领域）数量激增至1250多种，不仅远超欧盟，还几乎追平了美国的1440种。数量 之外，中国研制的新型药物还在不断突破高门槛，赢得全球最严苛的药品监管机构和西方制药巨头的认可。 | NAME | NET WORTH | COMPANY | RESIDENCE | CITIZENSHIP | | --- | --- | --- | --- | --- | | Zhong Huijuan | $17.2B | Hansoh Pharmaceutical Group | Shan ...

Industry Overview - The medical beauty injection materials industry in China has a limited number of publicly listed companies, primarily including Huaxi Biological, Haohai Biological, Aimeike, and Juzhi Biological, with most companies involved in the supply of upstream raw materials [1][7]. Company Summaries - Huaxi Biological is a global leader in hyaluronic acid, with a projected revenue of 53.71 billion yuan in 2024, and has expanded into collagen products through acquisitions [2][9]. - Haohai Biological has secured exclusive rights for domestic and international botulinum toxin products and is focusing on a dual product line of hyaluronic acid and botulinum toxin [6][15]. - Aimeike is expected to generate approximately 29.60 billion yuan in sales for its medical beauty injection materials in 2024, emphasizing high-end products [9][15]. - Juzhi Biological is projected to achieve sales of around 55.20 billion yuan in 2024, focusing on collagen products and leading the industry in standard-setting [9][15]. Sales and Production Data - Huaxi Biological has sold over 10 million units of its products, while Haohai Biological and Aimeike have sales around 7 million units each [13]. - Juzhi Biological's collagen products have a sales volume of approximately 55.20 billion yuan, indicating a strong market presence [11][13]. Business Strategies - Huaxi Biological is focusing on core technologies in glyco-biology and cell biology, aiming to enhance its position in the extracellular matrix and anti-aging sectors [15]. - Haohai Biological is pursuing international collaborations and technology imports to strengthen its product offerings and market competitiveness [15]. - Aimeike is developing a high-end product matrix centered on regenerative materials, with significant investments in training and technology [15]. - Juzhi Biological is leading the development of industry standards and expanding its product offerings in the collagen segment [15]. Regional Distribution - The majority of medical beauty injection material companies are concentrated in Shandong Province, with key players in raw material production and equipment manufacturing [7].

Core Viewpoint - The article discusses the significant decline in the wealth of Jian Jun, the leader of Aimeike, a prominent player in the medical beauty industry, highlighting the challenges faced by the company amid increasing competition and changing market dynamics [2][3]. Group 1: Wealth Decline of Jian Jun - Jian Jun's wealth has decreased from 525 billion yuan in 2023 to 220 billion yuan in 2025, a loss of 305 billion yuan over two years [2][3]. - Aimeike, under Jian Jun's leadership, has become a leading company in the medical beauty sector, forming a competitive landscape with Huaxi Biological and Haohai Biological, known as the "three swordsmen of hyaluronic acid" [2][3]. - Despite previous high growth rates, Aimeike's revenue and net profit growth have slowed to single digits in 2024, with both metrics turning negative in Q1 2025 [2][10]. Group 2: Aimeike's Business Performance - Aimeike's revenue surged by 104.13% in 2021, reaching 1.448 billion yuan, with net profit increasing by 117.81% to 958 million yuan [10]. - In 2023, Aimeike's revenue reached 2.869 billion yuan, and net profit was 1.858 billion yuan, but growth rates fell to 5.45% and 5.33% respectively in 2024 [11]. - The company's gross margin has also declined, from 95.09% in 2023 to 93.85% in Q1 2025 [11]. Group 3: Strategic Moves and Acquisitions - In March 2025, Aimeike announced plans to acquire 85% of South Korean REGEN Biotech, Inc. for 1.9 billion USD, aiming to enhance its international presence and product offerings [12][13]. - The acquisition is seen as a strategic move to solidify Aimeike's leading position in the injectable product market and to drive future growth [13][14]. - Analysts believe that this overseas acquisition could provide new growth opportunities for Aimeike amid a challenging domestic market [12][13].